Skip to main content

Table 3 Local tumor response

From: Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma

Response, n (%)

1 month

3 months

6 months

Complete response

0 (0.0)

0 (0.0)

0 (0.0)

Partial response

9 (42.9)

4 (28.6)

2 (20.0)

Stable disease

9 (42.9)

6 (42.9)

2 (20.0)

Progressive disease

3 (14.3)

4 (28.6)

6 (60.0)

ORR

9 (42.9)

4 (28.6)

2 (20.0)

DCR

18 (85.7)

10 (71.4)

4 (40.0)

  1. DCR disease control rate, ORR objective response rate